Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) has announced a quarterly dividend of 23.6 cents per share of common stock. The dividend will be paid on October 23, 2024, to shareholders of record as of the close of business on October 1, 2024. This announcement demonstrates Agilent's commitment to returning value to shareholders through regular dividend payments. However, it's important to note that the timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors, indicating potential flexibility in the company's dividend policy.
Politan Capital Management, an 8.9% shareholder of Masimo (NASDAQ: MASI), has issued an open letter to shareholders ahead of the company's 2024 Annual Meeting on September 19. The letter highlights the need for further change in Masimo's boardroom and refutes the company's defensive rhetoric. Politan urges shareholders to vote for its independent nominees, Darlene Solomon and William Jellison, on the WHITE card.
Key points from the letter include:
- Criticism of Masimo's board for lack of oversight and transparency
- Allegations of collusion between Masimo's CEO and RTW to manipulate voting
- Refutation of Masimo's claims about potential business disruption
- Defense against Masimo's accusations towards Politan
- Emphasis on the urgent need for change in Masimo's governance
Politan argues that without a majority of independent directors, Masimo's pattern of poor governance and shareholder value destruction will continue.
Agilent Technologies Inc. (NYSE: A) has launched its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, after receiving a California State clinical laboratory license and CLIA certificate of compliance. The BCSL will support drug development from early clinical studies through regulatory approval, offering efficient companion diagnostic development. It provides access to innovative technologies for biomarker assessment and high-quality assays for clinical trials.
The continuous development model from feasibility to FDA approval offers significant cost and time advantages for biopharma companies investing in companion diagnostics and precision therapeutics. This launch strengthens Agilent's capabilities in early assay development, technology innovation, and prospective clinical trial patient testing, reinforcing its commitment to the biopharma, clinical diagnostics, and precision medicine sectors.
Agilent Technologies Inc. (NYSE: A) reported Q3 FY2024 results with revenue of $1.58 billion, down 5.6% reported and 4.4% core year-over-year. GAAP EPS was $0.97, up 155% from Q3 FY2023, while non-GAAP EPS was $1.32, down 8%. Despite challenging market conditions, the company exceeded guidance. Agilent revised its full-year revenue outlook to $6.450-$6.500 billion and non-GAAP EPS guidance to $5.21-$5.25. Q4 revenue is expected at $1.641-$1.691 billion with non-GAAP EPS of $1.38-$1.42. The company is focusing on strategic transformation initiatives to drive margin expansion and growth.
Agilent Technologies Inc. (NYSE: A) has launched its new Agilent J&W 5Q GC/MS Columns, marking a significant advancement in gas chromatography/mass spectrometry (GC/MS) column technology. These columns combine ultra-inert performance and ultra-low-bleed technology, offering unmatched performance and durability for demanding applications. The J&W 5Q columns provide exceptional peak symmetry for active analytes and set a new industry standard for minimal column bleed, enabling high sensitivity and accurate quantitation for challenging trace-level analytes.
Key features include faster conditioning and increased resistance to conditions that can shorten column life. The columns enhance system performance in difficult conditions, such as using hydrogen as a carrier gas, and in environmental workflows targeting emerging analytes of interest. Available in various dimensions, they cater to a wide range of markets and applications, including PFAS testing in environmental samples and residual pesticide analysis in food.
Agilent Technologies Inc. (NYSE: A) has received FDA approval for MAGE-A4 IHC 1F9 pharmDx as a diagnostic tool to identify patients with synovial sarcoma eligible for treatment with TECELRA®, a MAGE-A4-directed engineered T-Cell Receptor (TCR) therapy. This immunohistochemistry (IHC) assay detects MAGE-A4 expression in formalin-fixed paraffin-embedded (FFPE) synovial sarcoma tissue. It's the first IVD for MAGE-A4 available on the market. TECELRA® is approved for advanced MAGE-A4 positive synovial sarcoma in adults with certain HLA types who have received prior chemotherapy, marking the first FDA-approved engineered TCR T-Cell therapy for a solid tumor cancer.
Agilent Technologies Inc. (NYSE: A) has acquired Sigsense Technologies, a San Francisco-based startup specializing in AI-enabled lab operations technology. The acquisition, for undisclosed financial terms, integrates Sigsense's AI and power monitoring technology into Agilent's CrossLab Connect suite of digital applications. This integration enhances asset monitoring capabilities, allowing labs to track instrument utilization and status across all scientific assets, regardless of vendor.
The technology provides operational insights to alert lab managers of underperforming assets and optimization opportunities, particularly beneficial for commercial labs with large instrument fleets and intense testing schedules. With this acquisition, Sigsense's employees, IP, and assets are now part of the Agilent CrossLab Group, further extending AI technology to improve lab performance and productivity.
Agilent Technologies Inc. (NYSE: A) has announced a $925 million acquisition of BIOVECTRA, a leading specialized contract development and manufacturing organization (CDMO) based in Canada. This strategic move expands Agilent's end-to-end biopharma solutions in three key areas:
1. Portfolio expansion: Adding sterile fill-finish services, pDNA and mRNA capabilities, and lipid nanoparticle formulation.
2. Rapidly growing modalities: Gaining expertise in antibody drug conjugates, highly potent active pharmaceutical ingredients, and GLP-1.
3. Gene editing capabilities: Combining BIOVECTRA's biologics expertise with Agilent's gRNA knowledge.
BIOVECTRA reported $113 million in revenue for 2023 and expects double-digit growth in 2024. The acquisition is expected to close before 2025 and will be $0.05 dilutive to Agilent's non-GAAP EPS in the first full year after closing.
Agilent Technologies (NYSE: A) has announced it will release its third-quarter fiscal year 2024 financial results after the stock market closes on August 21. The company will host a conference call at 1:30 p.m. PDT to discuss the results. Investors can join the listen-only webcast through the Events section of Agilent's investor relations website. A recording of the call will be available on the website for 90 days following the event. This announcement provides an opportunity for investors and analysts to gain insights into Agilent's recent financial performance and future outlook.
Agilent Technologies (NYSE: A) has announced the appointment of Bret DiMarco as its new senior vice president and chief legal officer, effective immediately. DiMarco will also serve as the company secretary. He brings a wealth of experience from his previous roles, including chief legal officer at Pendo.io and executive vice president, chief legal officer at Coherent Inc., where he handled legal matters, intellectual property, and global trade compliance. DiMarco has also been a special adviser during Coherent's merger with II-VI Incorporated and has a background in corporate and securities law from Wilson Sonsini Goodrich & Rosati. He is the current chair of the Nasdaq Exchange Nominating Committee and has been an adjunct assistant professor at the University of California Law School, San Francisco since 2004.